SCHEMBL7041301

SCHEMBL7041301

CCCCCCCCCCCCN=C(N)NCl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
SIGMAR1 Q99720 3/20 0.52
GRIN2D O15399 1/20 0.52
GRIN3B O60391 1/20 0.52
GRIN1 Q05586 1/20 0.52
GRIN2A Q12879 1/20 0.52
GRIN2B Q13224 1/20 0.52
GRIN2C Q14957 1/20 0.52
GRIN3A Q8TCU5 1/20 0.52
SCNN1A P37088 2/20 0.48
USP2 O75604 3/20 0.47
TP53 P04637 2/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47
HIF1A Q16665 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5178061 1.00 MEN1 (0.59) MEN1KMT2ASIGMAR1GRIN2DGRIN3B
SCHEMBL5486628 0.91
SCHEMBL9415798 0.81 MEN1 (0.61) MEN1KMT2ASIGMAR1GRIN2DGRIN3B
SCHEMBL9290906 0.81 MEN1 (0.61) MEN1KMT2ASIGMAR1GRIN2DGRIN3B
SCHEMBL6159793 0.79 GRIN2D (0.62) MEN1KMT2ASIGMAR1GRIN2DGRIN3B
SCHEMBL1738252 0.78 CYP1A2 (0.56) CYP1A2ALOX15BLM
SCHEMBL1738255 0.78 CYP1A2 (0.56) CYP1A2ALOX15BLM
SCHEMBL9059398 0.78 MEN1 (0.58) MEN1KMT2ASIGMAR1GRIN2DGRIN3B
SCHEMBL4575003 0.78 MEN1 (0.58) MEN1KMT2ASIGMAR1GRIN2DGRIN3B
SCHEMBL1273740 0.78 GRIN2D (0.78) MEN1KMT2ASIGMAR1GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120115133-A Synthesis method and application of ionic liquid and ZIF-8 composite material 北京工商大学 2025-06-10 CN claimed
CN-120115133-A Synthesis method and application of ionic liquid and ZIF-8 composite material 北京工商大学 2025-06-10 CN disclosed
EP-1295602-A1 OXYGEN-CONTAINING OPHTHALMIC COMPOSITION ROHTO PHARMACEUTICAL CO., LTD. (JP) 2003-03-26 EP disclosed
US-20020164379-A1 Oxygen-containing ophthalmic composition ROHTO PHARMACEUTICAL CO., LTD. (JP) 2002-11-07 US disclosed
US-4797352-A FIXING LIQUID CONTAINING GUANIDINE, MORPHOLINE ETC. KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1989-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020164379-A1 Oxygen-containing ophthalmic composition OGFOD1, HIF1A, HAO2 MEN1 4713/4885KMT2A 4318/4885SIGMAR1 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.